Ticagrelor — P2Y12 platelet inhibitor. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Ticagrelor
Brands
Brilinta
Class
P2Y12 platelet inhibitor
Mechanism
Reversibly binds the platelet P2Y12 ADP receptor, preventing signal transduction and platelet activation.
Used for
Reduction of cardiovascular death, myocardial infarction and stroke risk in adults with acute coronary syndrome or prior myocardial infarction; Reduction of stent thrombosis in adults stented for acute coronary syndrome
Common side effects
Bleeding; Dyspnea
Boxed warning
Significant, sometimes fatal bleeding; avoid with active bleeding or intracranial hemorrhage history.
Warnings
Dyspnea; Severe hepatic impairment; False-negative HIT platelet function tests
Label date: 20260901 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Prodrug; active metabolite irreversibly binds P2Y12 ADP receptors on platelets, inhibiting platelet activation and aggregation.
On both cards: Common side effects — Bleeding · Interactions — Opioids
Only on the Clopidogrel card: Used for — Acute coronary syndrome (NSTE-ACS, STEMI); Recent MI, recent stroke; Established peripheral arterial disease · Common side effects — Epistaxis; Hematuria; Bruising · Warnings — Avoid omeprazole or esomeprazole; Bleeding risk; Premature discontinuation raises CV risk · Interactions — Omeprazole, esomeprazole (CYP2C19 inhibitors); NSAIDs, warfarin, SSRIs, SNRIs
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Boxed warnings on related cards
Clopidogrel: Reduced antiplatelet effect in patients with two loss-of-function CYP2C19 alleles (poor metabolizers).
Capsera